PET/CT is a vital tool in the diagnosing, staging and restaging of cancers. PET is the nuclear portion of the hybrid camera system that detects cancerous tumors on a physiological level. Radioisotopes are utilized in localizing in the body without any harmful side effects. The CT is the other portion of the hybrid camera system to anatomically locate the cancerous tumors the PET detects. This enables oncology to form an effective treatment plan and monitor a patient’s treatment throughout the course of treatment. Initially, your doctor may refer you for a PET/CT scan to pinpoint the location where the cancer began and identify or rule out any additional places where it may have spread. Using non- invasive PET and CT imaging in combination can also help reduce or eliminate the need for exploratory surgery or biopsies.
PET/CT is also used for certain brain conditions such as Alzheimer disease and dementia as well as to assess heart muscle. We are a research imaging facility that is at the forefront on all areas of PET/CT imaging. We offer the newest and most innovative PET/CT studies that are in trials as well as recently FDA-approved exams.
For more information on this and other radiology procedures, please visit www.radiologyinfo.org.
PET/CT EXAMS OFFERED
WHOLE BODY EVALUATION EXAMS
F-18 FDG – detection and staging of many types of cancer
F-18 NaF – detection and staging of bone cancer
F-18 Fluciclovine (Axumin) – staging and/or detection of recurrent prostate cancer
Coming soon: Ga-68 Dotatate – detection and staging of neuroendocrine tumors
BRAIN ONLY EXAMS
F-18 FDG – detection of Alzheimer’s/Dementia or brain tumor evaluation
F-18 Florbetapir – detection of Alzheimer disease
F-18 Florbetaben – detection of Alzheimer disease (ongoing research trial)
CARDIAC (HEART) EXAMS
F-18 FDG – Myocardial viability (i.e. assessment of heart muscle to help decide on coronary artery bypass surgery)
CURRENT CLINICAL TRIALS
EARLY ALZHEIMER'S DISEASE
Desert Medical Imaging, Halo Diagnostics' global center for innovation, is the imaging center for this 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer’s Disease.